Synoptis Industrial SP .zo.o Pharmaceutical Import Profile — Poland (DGFT 2022–2026)

Name: Synoptis Industrial SP .zo.o Pharmaceutical Import Records from India — 4 Products, $7.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Synoptis Industrial SP .zo.o — Pharmaceutical Importer Profile (2026) | 4 Products, $7.3M Trade | TransData Nexus

Synoptis Industrial SP .zo.o

Pharmaceutical Importer · Poland · Cardiovascular Focus · $7.3M Total Trade · DGFT Verified

Synoptis Industrial SP .zo.o is a pharmaceutical importer based in Poland with a total trade value of $7.3M across 4 products in 3 therapeutic categories. Based on 156 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Synoptis Industrial SP .zo.o sources from 1 verified Indian supplier, with Macleods Pharmaceuticals Limited accounting for 100.0% of imports.

Synoptis Industrial SP .zo.o — Import Portfolio & Supplier Network

Synoptis Industrial SP .zo.o import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Synoptis Industrial SP .zo.o?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Macleods Pharmaceuticals Limited	$9.3M	465	100.0%

Synoptis Industrial SP .zo.o sources from 1 verified Indian supplier across 269 distinct formulations. The sourcing is highly concentrated — Macleods Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Medicines. emtricitabine 200MG +	$727.8K	16
Drugs and pharmaceuticals harmless	$565.4K	23
Drugs and pharmaceuticals harmlessmedicines emtricitabine and tenofovir disoproxil film coated tablets	$400.0K	8
Drugs and pharmaceuticals harmless medicines emtricitabine and tenofovir disoproxil film coated tablets (200 MG/ 245 MG)	$168.5K	5
Exorta 10 MG 28 tabl (rosuvastatin 10 mgtablets)bno. 14250022a & 14250025a mfgdt:01/2025 exp dt:12/2027 ps: 4x7s	$150.0K	3
Drugs and pharmaceuticals harmless medicines tenofovir disoproxil film coated tablets 245 MG	$148.8K	6
Medicines. efavirenz 600MG + emtricitabine 200MG + tenofovir disoproxil fumarate300mg	$148.6K	4
Drugs and pharmaceuticals harmless medicines emtricitabine and tenofovir disoproxil film coated tablets(200MG/245MG)	$146.7K	3
Cinacalcet hydrochloride 30MG tablets	$136.1K	4
Exorta 5 MG 28 tabl (rosuvastatin 5 MG tablets)bno. 14250105a to 14250109a md. 01/25 ed. 12/27 ps: 4x7s	$117.3K	3
Carbimazole 20MG tablets, bn. bci2201a	$100.0K	2
Drugs and pharmaceuticals harmlessmedicines tenofovir disoproxil film coated tablets 245 MG	$100.0K	2
Drugs and pharmaceuticals harmlessmedicines emtricitabina tenofovirdisoproxilo macleods 200MG/245MG	$100.0K	2
Pantoprazole genoptim enteric coated TAB	$95.6K	4
Tadalafil tablets 5 MG (tadaxin 5 MG) bno:14240632a mfg dt:05/2024 exp dt:04/2027	$89.6K	2

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Rosuvastatin	Cardiovascular	$3.4M	68	0.7%	15
2	Emtricitabine	Antiviral & HIV Medications	$2.8M	64	1.6%	10
3	Clopidogrel	Cardiovascular	$800.0K	16	0.3%	7
4	Efavirenz	Antivirals	$342.4K	8	0.6%	17

Synoptis Industrial SP .zo.o imports 4 pharmaceutical products across 3 categories into Poland totaling $7.3M.

Synoptis Industrial SP .zo.o — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Synoptis Industrial Sp. z o.o. is a Polish pharmaceutical company specializing in the import and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Headquartered in Toruń, Poland, at ul. Forteczna 35-37, the company operates as a subsidiary of the Neuca S.A. Capital Group, a leading pharmaceutical wholesaler in Poland listed on the Warsaw Stock Exchange. Neuca S.A. has over 30 years of experience in the pharmaceutical industry, serving the pharmacy, hospital, and medical markets.

Synoptis Industrial plays a pivotal role in Poland's pharmaceutical distribution network by importing a diverse range of pharmaceutical products and medical devices. The company's operations encompass quality control testing, packaging, labeling, serialization, warehousing, transport, and clinical trial logistics. This comprehensive service offering positions Synoptis Industrial as a key player in ensuring the availability and distribution of essential pharmaceutical products across Poland.

2Distribution Network

Synoptis Industrial's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products throughout Poland. The company's logistics capabilities include warehousing, transport, and clinical trial logistics, which are integral to its operations. While specific details about warehouse locations and geographic coverage are not publicly disclosed, Synoptis Industrial's affiliation with Neuca S.A., the largest pharmaceutical wholesaler in Poland, suggests a well-established and extensive distribution infrastructure. This infrastructure likely facilitates the company's ability to serve the pharmacy, hospital, and medical markets effectively.

3Industry Role

In Poland's pharmaceutical supply chain, Synoptis Industrial Sp. z o.o. functions primarily as a pharmaceutical importer and distributor. The company imports finished pharmaceutical formulations from various international suppliers, including India, and manages their distribution within Poland. Synoptis Industrial's comprehensive services, such as quality control testing, packaging, labeling, serialization, warehousing, transport, and clinical trial logistics, underscore its role as a key intermediary between international manufacturers and the Polish market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Synoptis Industrial SP .zo.o

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Synoptis Industrial's sourcing strategy exhibits a high degree of concentration, with a total import value of $7.3 million USD from India over 156 shipments, primarily from a single supplier, Macleods Pharmaceuticals Limited. This single-source dependency may present risks, such as supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges within the supplier's facilities. However, the consistent volume of imports and the long-standing relationship with Macleods Pharmaceuticals Limited suggest a stable and reliable partnership. The company's focus on a limited number of suppliers may also allow for more favorable terms and streamlined logistics. Nonetheless, diversifying the supplier base could mitigate potential risks associated with over-reliance on a single source.

2Supply Chain Resilience

Synoptis Industrial's supply chain resilience is closely tied to its relationship with Macleods Pharmaceuticals Limited, the sole supplier of its imported pharmaceutical products. The company's import data indicates a consistent flow of shipments, reflecting a stable supply chain. However, the lack of publicly available information regarding backup suppliers and the diversity of formulations imported suggests a potential vulnerability to disruptions. To enhance resilience, Synoptis Industrial could consider establishing relationships with additional suppliers and diversifying its product portfolio. Ensuring that all suppliers comply with international Good Manufacturing Practice (GMP) standards is crucial for maintaining product quality and regulatory compliance.

Importing Pharmaceuticals into Poland — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Poland

1Regulatory Authority & Framework

In Poland, the Chief Pharmaceutical Inspectorate (GIF) is the primary regulatory authority overseeing the import and distribution of medicinal products. The Pharmaceutical Law of 6 September 2001, as amended, governs the importation of medicinal products into Poland. According to this legislation, any activity involving the importation of a medicinal product into Poland from outside the European Union or European Free Trade Association (EFTA) countries, which includes storage, quality control at batch release, and distribution, constitutes an import requiring GIF authorization. (cms.law)

2Import Licensing & GMP

Importers of medicinal products into Poland must obtain authorization from the Chief Pharmaceutical Inspectorate (GIF). This authorization is mandatory for activities such as storage, quality control at batch release, and distribution of imported medicinal products. (cms.law) Additionally, imported pharmaceutical products must comply with international Good Manufacturing Practice (GMP) standards, such as EU GMP, WHO GMP, or PIC/S certifications, to ensure product quality and safety. Importers are also required to hold a wholesale distribution authorization to legally distribute medicinal products within Poland.

Quality & Labeling

Synoptis Industrial SP .zo.o — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Synoptis Industrial's product strategy focuses on importing pharmaceutical formulations in the cardiovascular and antiviral therapeutic categories. The company's top five imported products include Rosuvastatin, Emtricitabine, Clopidogrel, and Efavirenz, which are essential in managing cardiovascular diseases and HIV infections. The market demand for these products is driven by the prevalence of cardiovascular conditions and HIV in Poland, necessitating a steady supply of effective treatments. By concentrating on these therapeutic areas, Synoptis Industrial aligns its product offerings with critical healthcare needs in the Polish market.

2Sourcing Profile

Synoptis Industrial's sourcing strategy is centered on importing generic pharmaceutical formulations from India, particularly from Macleods Pharmaceuticals Limited. The company's focus on finished pharmaceutical products, rather than raw active pharmaceutical ingredients (APIs), indicates a preference for ready-to-market solutions that meet Polish regulatory standards. India's robust pharmaceutical manufacturing sector, known for its compliance with international GMP standards, makes it a strategic sourcing partner for Synoptis Industrial.

3Market Positioning

Seller's Guide — How to Become a Supplier to Synoptis Industrial SP .zo.o

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a potential opportunity for new Indian suppliers to enter the Polish market by partnering with Synoptis Industrial. To capitalize on this opportunity, Indian exporters should focus on offering high-quality generic formulations that comply with EU GMP standards, competitive pricing, and reliable supply capabilities. Identifying and addressing any gaps in Synoptis Industrial's current sourcing, such as unmet therapeutic needs or product shortages, could further enhance the attractiveness of new suppliers.

2Requirements & Qualifications

Indian exporters aiming to supply Synoptis Industrial and the Polish market must ensure that their products meet international GMP standards, such as EU GMP, WHO GMP, or PIC/S certifications. Additionally, obtaining marketing authorization from the Chief Pharmaceutical Inspectorate (GIF) is essential for the legal distribution of medicinal products in Poland. Compliance with Polish labeling requirements, including the use of the Polish language and adherence to serialization mandates, is also necessary.

3How to Approach

Frequently Asked Questions — Synoptis Industrial SP .zo.o

What products does Synoptis Industrial SP .zo.o import from India?

Synoptis Industrial SP .zo.o imports 4 pharmaceutical products across 3 categories. Top imports: Rosuvastatin ($3.4M), Emtricitabine ($2.8M), Clopidogrel ($800.0K), Efavirenz ($342.4K).

Who supplies pharmaceuticals to Synoptis Industrial SP .zo.o from India?

Synoptis Industrial SP .zo.o sources from 1 verified Indian suppliers. The primary supplier is Macleods Pharmaceuticals Limited (100.0% of imports, $9.3M).

What is Synoptis Industrial SP .zo.o's total pharmaceutical import value?

Synoptis Industrial SP .zo.o's total pharmaceutical import value from India is $7.3M, based on 156 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Synoptis Industrial SP .zo.o focus on?

Synoptis Industrial SP .zo.o imports across 3 categories. The largest: Cardiovascular (57.3%), Antiviral & HIV Medications (38.0%), Antivirals (4.7%).

Get Full Synoptis Industrial SP .zo.o Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.